Sangamo Therapeutics
Sangamo Therapeutics, Inc. is an American biotechnology company based in Brisbane, California. It applies cell and gene therapy to combat haemophilia and other genetic diseases.History
The company was founded in 1995 in Richmond, California. It was originally known as Sangamo Biosciences, Inc. before changing names in 2017. In September 2018, it had 182 employees. Sandy Macrae is the president. In 2018, Edward Rebar became the senior vice president and chief technology officer of Sangamo.Research
Sangamo applies technology to treat haemophilia B and lysosomal storage diseases including mucopolysaccharidosis type I and mucopolysaccharidosis type II. The FDA granted Sangamo fast track designation for SB-525, a gene therapy candidate for haemophilia A. In its partnership with Pfizer in 2017, Sangamo uses Bioverativ in hemoglobinopathies such as beta thalassemia and sickle cell disease. It is also developing zinc finger gene editing technology.
In February 2019, medical scientists, working with Sangamo Therapeutics, announced the first ever "in body" human gene editing therapy to permanently alter DNA - in a patient with Hunter Syndrome. Clinical trials by Sangamo involving gene editing using Zinc Finger Nuclease are ongoing.
